IL261195B - Combined treatment for ovarian cancer - Google Patents

Combined treatment for ovarian cancer

Info

Publication number
IL261195B
IL261195B IL261195A IL26119518A IL261195B IL 261195 B IL261195 B IL 261195B IL 261195 A IL261195 A IL 261195A IL 26119518 A IL26119518 A IL 26119518A IL 261195 B IL261195 B IL 261195B
Authority
IL
Israel
Prior art keywords
treatment
ovarian cancer
combination therapy
therapy
ovarian
Prior art date
Application number
IL261195A
Other languages
English (en)
Hebrew (he)
Other versions
IL261195A (en
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of IL261195A publication Critical patent/IL261195A/en
Publication of IL261195B publication Critical patent/IL261195B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL261195A 2016-02-29 2018-08-16 Combined treatment for ovarian cancer IL261195B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301225P 2016-02-29 2016-02-29
PCT/US2017/019843 WO2017151554A1 (en) 2016-02-29 2017-02-28 Combination therapy for treatment of ovarian cancer

Publications (2)

Publication Number Publication Date
IL261195A IL261195A (en) 2018-10-31
IL261195B true IL261195B (en) 2022-06-01

Family

ID=59744380

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261195A IL261195B (en) 2016-02-29 2018-08-16 Combined treatment for ovarian cancer

Country Status (9)

Country Link
US (1) US11154538B2 (cg-RX-API-DMAC7.html)
EP (1) EP3423048A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019508429A (cg-RX-API-DMAC7.html)
CN (1) CN108697666A (cg-RX-API-DMAC7.html)
AU (2) AU2017227534A1 (cg-RX-API-DMAC7.html)
CA (1) CA3014680A1 (cg-RX-API-DMAC7.html)
IL (1) IL261195B (cg-RX-API-DMAC7.html)
MX (1) MX2018010223A (cg-RX-API-DMAC7.html)
WO (1) WO2017151554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
KR20200106053A (ko) * 2017-12-29 2020-09-10 버텍스 파마슈티칼스 인코포레이티드 Atr 억제제를 사용한 암 치료 방법
JP2021510702A (ja) 2018-01-12 2021-04-30 プロリンクス エルエルシー 相乗的がん治療
EP3966782A2 (en) 2019-05-06 2022-03-16 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
JPWO2023157891A1 (cg-RX-API-DMAC7.html) 2022-02-16 2023-08-24
WO2024111564A1 (ja) * 2022-11-21 2024-05-30 富士フイルム株式会社 トポテカン又はその塩を内包するリポソーム組成物およびdna損傷修復阻害剤を含む組合せ医薬
CN116024162B (zh) * 2023-02-27 2025-01-10 山东大学 Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用
TW202502354A (zh) * 2023-06-02 2025-01-16 美商薩諾管理公司 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症
CN117860753A (zh) * 2023-11-30 2024-04-12 华中科技大学 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
EP2714033A1 (en) * 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
WO2013067162A1 (en) * 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
JP6114075B2 (ja) * 2013-03-07 2017-04-12 三菱航空機株式会社 航空機の警報システム、及び、航空機
US20160120848A1 (en) * 2013-05-21 2016-05-05 Synta Pharmaceuticals Corp. Specific cancer treatment regimes with ganetespib
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens

Also Published As

Publication number Publication date
JP2024054312A (ja) 2024-04-16
MX2018010223A (es) 2018-11-09
US11154538B2 (en) 2021-10-26
CN108697666A (zh) 2018-10-23
CA3014680A1 (en) 2017-09-08
WO2017151554A1 (en) 2017-09-08
US20190060285A1 (en) 2019-02-28
AU2023200554A1 (en) 2023-03-02
JP2019508429A (ja) 2019-03-28
EP3423048A1 (en) 2019-01-09
AU2017227534A1 (en) 2018-08-30
JP2022079569A (ja) 2022-05-26
IL261195A (en) 2018-10-31
EP3423048A4 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
IL263925A (en) Methods of treating ovarian cancer
IL256224B (en) Combined therapy for cancer treatment
IL255060A0 (en) Combined treatment for cancer
IL267795A (en) Combined treatment for cancer
IL258521A (en) Combination of treatments for cancer treatment
IL258580B (en) Combined therapy for the treatment of malignancies
SMT202100245T1 (it) Trattamento combinato del cancro
IL265697A (en) Prostate cancer treatment
IL257073A (en) Combined therapies for cancer treatment
IL262342A (en) Cancer treatment methods
EP3226901A4 (en) Combination therapy for treatment of cancer
EP3185884A4 (en) Combination therapy for treatment of cancer
IL263835A (en) Exosome-guided treatment of cancer
IL266993A (en) Combined therapy for cancer treatment
IL274748A (en) Improved cancer treatment
IL253642A0 (en) Combined treatment for cancer
HK40002648A (en) Combination therapy for treatment of ovarian cancer
GB201704474D0 (en) Combination therapy for treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer